SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Gynecological Oncology
This article is part of the Research TopicAdvances in Ovarian Cancer TherapeuticsView all 7 articles
Comparative Effectiveness and Safety of Immunotherapeutic Strategies in Ovarian Cancer: A Systematic Review and Network Meta-Analysis
Provisionally accepted
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Ovarian cancer remains the most lethal gynecologic malignancy, with poor survival despite standard therapies. Immunotherapy represents a promising option, yet the comparative efficacy and safety among different immunotherapies are unclear. This network meta-analysis aimed to evaluate and rank multiple immunotherapeutic strategies for ovarian cancer. Methods: A systematic search of PubMed, Embase, Medline, PsycINFO, Cochrane Central Register of Controlled Trials, and Web of Science was performed through May 31, 2025. Randomized controlled trials (RCTs) comparing immunotherapies were included. Outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), treatment-related adverse events (TRAEs), and grade ≥3 adverse events. Bayesian network meta-analysis was conducted using random-effects models, calculating standardized mean differences (SMDs) or mean differences (MDs) with 95% confidence intervals (CIs) for continuous variables, and odds ratios (ORs) with 95% CIs for categorical variables. Results: Twenty-six RCTs involving 5,982 patients were included. Cancer vaccines (CV) (HR = 0.56, 95% CI 0.43–0.73) and dual immune checkpoint blockade (DICB) (HR = 0.65, 95% CI 0.46–0.92) significantly improved OS compared with controls. CV also prolonged PFS (SMD = 0.95, 95% CI 0.16–1.75). CTLA-4 inhibitors markedly increased ORR (OR = 99.32, 95% CI 1.18–8360.43), though no significant DCR differences were observed. PD-1 inhibitors demonstrated the best safety profile, reducing grade ≥ 3 AEs (OR = 0.16, 95% CI 0.08–0.33) and overall TRAEs versus other immunotherapies. Conclusion: CV and DICB yielded the most consistent survival benefits, while PD-1 inhibitors showed superior safety. These findings support tailored, biomarker-informed immunotherapy approaches and combination strategies to optimize efficacy and tolerability in ovarian cancer. Further head-to-head trials are warranted to confirm these results.
Keywords: ovarian cancer, Immunotherapy, Cancer Vaccines, immune checkpoint inhibitors, Network meta-analysis
Received: 04 Jul 2025; Accepted: 21 Oct 2025.
Copyright: © 2025 Wang, Zhang, Xie, Liu, Cui and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Min Feng, fengminbucm@foxmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.